Research found that abciximab intravenous drugs for patients with acute myocardial infarction and the ones who has one-time coronary artery is no profit. Coronary artery to medicine can reduce the incidence of heart failure. In through the blood clots analyzer test results indicate that the 7% patients with coronary artery to medicine group of death, and intravenous treatment group was 7.6%, there was no significant difference. Coronary artery patients with heart failure treatment group of lower incidence vein treatment group. Abciximab coronary artery to drug safety and not a significant increase in the risk of bleeding.
ISAR-REACT 4 research (randomized double-blind design) found that, compared with Bivalirudin, abciximab and ordinary heparin failed to significantly reduce/death and heart attacks, and serious bleeding rate significantly increased. The study included 1721 patients without st-segment elevation acute myocardial infarction (NSTEMI) patients, and the random points into abciximab and ordinary heparin group than cut LuDing/or group. The main events of the composite end point for 30 days for all, and death, and again hair large myocardial infarction, emergency target blood vessels reascularization or massive haemorrhage, secondary end points for death, any again hair myocardial infarction, or emergency target blood vessels reascularization (efficacy end point) and serious hemorrhage (safety end). The results showed that single of o company general heparin group, fell LuDing/than the main end event rates of 10.9% and 11.0% respectively, secondary efficacy end point event rates were 12.8% and 13.4% respectively. In safety, and LuDing group than coming, compared with common abciximab heparin group/serious bleeding significantly increased incidence (2.6% to 4.6%).
ADOPT study (randomized double-blind design) found that review, sand class 30 days of treatment venous thromboembolism (VTE) prevention effect, no better than enoxaparin for 1 ~ 2 weeks, and significantly increased bleeding events. The study included 6528 patients with congestive heart failure, acute respiratory failure and infected patients, random to enoxaparin (40 mg, qd) subcutaneous injection 6 to 14 days, sand class with aripiprazole (2.5 mg, bid) oral 30 days treatment, compare the two treatment on hospital in patients with venous thromboembolism (VTE) prevention effect. The results showed that enoxaparin and review of the team, sand VTE rate were 3.1% and 2.7% respectively, both no significant differences. And enoxaparin compared to review the shift of the bleeding, sand significantly higher rates (0.19% to 0.47%).
TRACER research (multicenter, randomized double-blind design) found that, compared with placebo, Vorapaxar (new selective protease activation receptor-1) failed to significantly improve the st-segment elevation in patients with acute coronary syndromes prognosis, and significant increases in serious bleeding and incidence of intracerebral hemorrhage. The study included 12944 patients without st-segment elevation in patients with acute coronary syndromes, random be Vorapaxar (new selective protease activation receptor-1) or a placebo. Vorapaxar starting load is 40 mg, then to 2.5 mg/d oral. The primary end point for cardiovascular death, myocardial infarction, stroke, because again hair ischemia and readmission to the hospital and emergency coronary artery blood luck reconstruction. Research results show that the 2 years of follow-up, Vorapaxar and placebo groups of the primary end point event rates were 18.5% and 19.9% respectively. In safety, compared with placebo, Vorapaxar group of GUSTO moderate to severe bleeding events (5.2% to 7.2%) and intracranial bleeding events (0.24% to 1.07%) increased significantly.
ATLAS ACS 2-TIMI research (randomized double-blind design) found that, compared with placebo, and cut sand class (2.5 mg, bid) used for acute coronary syndrome patients in hospital, significantly reduce the death, heart attack and stroke incidence; At the same time the significant rise and coronary artery bypass irrelevant to the incidence and serious bleeding intracranial hemorrhage rate, related fatal bleeding incidence and placebo quite. The study included 15526 patients with acute coronary syndrome patients in hospital, randomly assigned to the sand fell 2.5 mg class (bid), 5 mg (bid) or a placebo. The primary end point for cardiovascular death, myocardial infarction, or stroke compound event. All participants will receive a small doses of aspirin and (or) [b] thiophene pyridine classes drug therapy. Results show that, compared with placebo, the sand fell significantly lower class the event rates in the primary end point (10.7% to 8.9%), and a significant rise and coronary artery bypass irrelevant to the incidence of serious bleeding (0.6% to 2.1%) and intracranial bleeding rate (0.2% to 0.6%), related fatal bleeding without obvious increase rate (0.2% to 0.3%).
ISAR-REACT 4 research (randomized double-blind design) found that, compared with Bivalirudin, abciximab and ordinary heparin failed to significantly reduce/death and heart attacks, and serious bleeding rate significantly increased. The study included 1721 patients without st-segment elevation acute myocardial infarction (NSTEMI) patients, and the random points into abciximab and ordinary heparin group than cut LuDing/or group. The main events of the composite end point for 30 days for all, and death, and again hair large myocardial infarction, emergency target blood vessels reascularization or massive haemorrhage, secondary end points for death, any again hair myocardial infarction, or emergency target blood vessels reascularization (efficacy end point) and serious hemorrhage (safety end). The results showed that single of o company general heparin group, fell LuDing/than the main end event rates of 10.9% and 11.0% respectively, secondary efficacy end point event rates were 12.8% and 13.4% respectively. In safety, and LuDing group than coming, compared with common abciximab heparin group/serious bleeding significantly increased incidence (2.6% to 4.6%).
ADOPT study (randomized double-blind design) found that review, sand class 30 days of treatment venous thromboembolism (VTE) prevention effect, no better than enoxaparin for 1 ~ 2 weeks, and significantly increased bleeding events. The study included 6528 patients with congestive heart failure, acute respiratory failure and infected patients, random to enoxaparin (40 mg, qd) subcutaneous injection 6 to 14 days, sand class with aripiprazole (2.5 mg, bid) oral 30 days treatment, compare the two treatment on hospital in patients with venous thromboembolism (VTE) prevention effect. The results showed that enoxaparin and review of the team, sand VTE rate were 3.1% and 2.7% respectively, both no significant differences. And enoxaparin compared to review the shift of the bleeding, sand significantly higher rates (0.19% to 0.47%).
TRACER research (multicenter, randomized double-blind design) found that, compared with placebo, Vorapaxar (new selective protease activation receptor-1) failed to significantly improve the st-segment elevation in patients with acute coronary syndromes prognosis, and significant increases in serious bleeding and incidence of intracerebral hemorrhage. The study included 12944 patients without st-segment elevation in patients with acute coronary syndromes, random be Vorapaxar (new selective protease activation receptor-1) or a placebo. Vorapaxar starting load is 40 mg, then to 2.5 mg/d oral. The primary end point for cardiovascular death, myocardial infarction, stroke, because again hair ischemia and readmission to the hospital and emergency coronary artery blood luck reconstruction. Research results show that the 2 years of follow-up, Vorapaxar and placebo groups of the primary end point event rates were 18.5% and 19.9% respectively. In safety, compared with placebo, Vorapaxar group of GUSTO moderate to severe bleeding events (5.2% to 7.2%) and intracranial bleeding events (0.24% to 1.07%) increased significantly.
ATLAS ACS 2-TIMI research (randomized double-blind design) found that, compared with placebo, and cut sand class (2.5 mg, bid) used for acute coronary syndrome patients in hospital, significantly reduce the death, heart attack and stroke incidence; At the same time the significant rise and coronary artery bypass irrelevant to the incidence and serious bleeding intracranial hemorrhage rate, related fatal bleeding incidence and placebo quite. The study included 15526 patients with acute coronary syndrome patients in hospital, randomly assigned to the sand fell 2.5 mg class (bid), 5 mg (bid) or a placebo. The primary end point for cardiovascular death, myocardial infarction, or stroke compound event. All participants will receive a small doses of aspirin and (or) [b] thiophene pyridine classes drug therapy. Results show that, compared with placebo, the sand fell significantly lower class the event rates in the primary end point (10.7% to 8.9%), and a significant rise and coronary artery bypass irrelevant to the incidence of serious bleeding (0.6% to 2.1%) and intracranial bleeding rate (0.2% to 0.6%), related fatal bleeding without obvious increase rate (0.2% to 0.3%).
没有评论:
发表评论